Centaur Pharmaceuticals submits ANDA for Dapagliflozin
Centaur Pharmaceuticals has submitted an Abbreviated New Drug Application (ANDA) for Dapagliflozin.
| Drug | MOA / Company | Stage |
|---|---|---|
| Dapagliflozin | Centaur Pharmaceuticals | Lead |
Focal Asset
Dapagliflozin
Company
Centaur Pharmaceuticals
Indication
Diabetes / SGLT2 Inhibitor
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
Centaur Pharmaceuticals' submission of an ANDA for Dapagliflozin marks a significant entry into the SGLT2 inhibitor market, intensifying competition among existing players. This could lead to shifts in pricing strategies and market dynamics that require close monitoring by portfolio teams.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor the FDA's review timeline and any subsequent approvals or market entries by Centaur Pharmaceuticals.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.